Biologics have become a fast-developing class of therapeutics. In addition to high specificity, they offer fewer side effects than traditional therapies and often engage host’s own immune system in fighting the disease. In 2024, five out of top ten bestselling drugs worldwide were biologics, approved for treating cancers, autoimmune and metabolic diseases.

There are numerous types of biologic therapeutics derived from antibodies and TCRs currently in Discovery & Development but, due to limited amount of information in the public domain, in silico affinity maturation and developability optimisation still require extensive biological validation. Epitope mapping by structural studies is one of the methods Evotec excels in. Our poster presents case studies on X-ray crystallography and cryoEM utilisation. With multiple services integrated within the company, Evotec is very well poised to provide a full biologics lead optimization package, incorporating the latest advances in software development.